TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07079475: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD6008 Combined With Sunvozertinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations (TIAN-SHAN8)

Sponsor: Dizal Pharmaceuticals · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,086,850

Rescue Site Savings

+$4,005,540

Unlock Full NCT07079475 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07079475 Rescue Dossier →